Angiotensin II-Receptor Antagonist Losartan Does not Prevent Nitroglycerin Tolerance in Patients with Coronary Artery Disease

[1]  J. Rouleau,et al.  Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. , 2003, Journal of the American College of Cardiology.

[2]  J. Yodoi,et al.  Attenuation of Nitrate Tolerance and Oxidative Stress by an Angiotensin II Receptor Blocker in Patients With Coronary Spastic Angina , 2003, Circulation.

[3]  T. Gori,et al.  Nitrate tolerance: a unifying hypothesis. , 2002, Circulation.

[4]  S. Bergmann,et al.  Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. , 2002, Journal of the American College of Cardiology.

[5]  L. T. McGrath,et al.  Platelet Nitric Oxide and Superoxide Release During the Development of Nitrate Tolerance: Effect of Supplemental Ascorbate , 2002, Circulation.

[6]  J. Stamler,et al.  Identification of the enzymatic mechanism of nitroglycerin bioactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Chen Yan,et al.  Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. , 2002, American journal of physiology. Heart and circulatory physiology.

[8]  J. Parker,et al.  The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. , 2002, Journal of the American College of Cardiology.

[9]  T. Gori,et al.  Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance: A Human In Vivo Study , 2001, Circulation.

[10]  J. Horowitz,et al.  Nitroglycerin Tolerance in Human Vessels: Evidence for Impaired Nitroglycerin Bioconversion , 2000, Circulation.

[11]  J. Parker,et al.  The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. , 1999, Journal of cardiovascular pharmacology.

[12]  E. Erdmann,et al.  Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. , 1999, Journal of the American College of Cardiology.

[13]  D. Harrison,et al.  Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. , 1999, Circulation.

[14]  Z. Vered,et al.  Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. , 1998, The American journal of cardiology.

[15]  ThomasMünzel,et al.  Long-term Angiotensin-Converting Enzyme Inhibition With High-Dose Enalapril Retards Nitrate Tolerance in Large Epicardial Arteries and Prevents Rebound Coronary Vasoconstriction In Vivo , 1996 .

[16]  P. Abete,et al.  Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia. , 1995, The American journal of cardiology.

[17]  D. Harrison,et al.  Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[19]  J. Parker,et al.  Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. , 1995, Circulation.

[20]  J. Parker,et al.  Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. , 1993, Journal of the American College of Cardiology.

[21]  T. Bradstreet,et al.  Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. , 1993, Hypertension.

[22]  P. Yock,et al.  Effect of Selective Angiotensin II Receptor Antagonism and Angiotensin Converting Enzyme Inhibition on the Coronary Vasculature In Vivo Intravascular Two‐dimensional and Doppler Ultrasound Studies , 1993, Circulation.

[23]  J. Parker,et al.  Counter‐Regulatory Responses to Continuous and Intermittent Therapy With Nitroglycerin , 1991, Circulation.

[24]  A. Wasserman,et al.  Prevention of Nitrate Tolerance With Angiotension Converting Enzyme Inhibitors , 1991, Circulation.

[25]  Y. Christen,et al.  Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II , 1991, Circulation.

[26]  J. Rouleau,et al.  Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. , 1990, Journal of the American College of Cardiology.

[27]  B. Lewis,et al.  Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. , 1990, The American journal of cardiology.

[28]  J. Parker.  Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. , 1989, Journal of the American College of Cardiology.

[29]  S. Gottlieb,et al.  Prevention and reversal of nitrate tolerance in patients with congestive heart failure. , 1987, The New England journal of medicine.

[30]  J. Anderson,et al.  Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. , 1987, The American journal of cardiology.

[31]  J. Parker,et al.  Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris. , 1985, The American journal of cardiology.

[32]  J. Parker,et al.  Transdermal Nitroglycerin in Angina Pectoris , 1984, The American journal of cardiology.

[33]  J. Parker,et al.  Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy. , 1984, The American journal of cardiology.

[34]  J. Parker,et al.  Nitrate tolerance: influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin. , 1983, Journal of the American College of Cardiology.

[35]  J. Parker,et al.  Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. , 1982, The American journal of cardiology.

[36]  E. Braunwald,et al.  Limitation of Experimental Infarct Size by an Angiotensin‐converting Enzyme Inhibitor , 1982, Circulation.

[37]  J. Parker,et al.  Tolerance to the Circulatory Effects of Oral Isosorbide Dinitrate: Rate of Development and Cross–tolerance to Glyceryl Trinitrate , 1980, Circulation.

[38]  P. Needleman,et al.  Mechanism of tolerance development to organic nitrates. , 1973, The Journal of pharmacology and experimental therapeutics.

[39]  Y. Sugishita,et al.  Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. , 1997, Circulation.

[40]  Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. , 1996, Journal of the American College of Cardiology.

[41]  D. Harrison,et al.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.